Who are similar placebo to mebendazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Colchicine Pill, Bevacizumab and Paclitaxel, NK105, Abraxane (Maintenance), Carboplatin+Paclitaxel, Placebo, docetaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/similar-placebo-to-mebendazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

similar placebo to mebendazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

similar placebo to mebendazole (similar placebo to mebendazole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthelmintic. Area: Infectious Diseases.

phase 3 Anthelmintic Beta-tubulin Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

similar placebo to mebendazole (similar placebo to mebendazole) — Swiss Tropical & Public Health Institute. This drug works by inhibiting the action of a specific enzyme involved in the lifecycle of parasitic worms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
similar placebo to mebendazole TARGET	similar placebo to mebendazole	Swiss Tropical & Public Health Institute	phase 3	Anthelmintic	Beta-tubulin
Colchicine Pill	Colchicine Pill	Brigham and Women's Hospital	marketed	Microtubule inhibitor / Anti-inflammatory agent	Beta-tubulin
Bevacizumab and Paclitaxel	Bevacizumab and Paclitaxel	Central European Cooperative Oncology Group	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) + taxane chemotherapy	VEGF (bevacizumab); beta-tubulin (paclitaxel)
NK105	NK105	Nippon Kayaku Co., Ltd.	phase 3	Microtubule inhibitor	Beta-tubulin
Abraxane (Maintenance)	Abraxane (Maintenance)	Celgene	phase 3	Microtubule stabilizer (taxane)	Beta-tubulin / microtubules
Carboplatin+Paclitaxel	Carboplatin+Paclitaxel	AstraZeneca	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); beta-tubulin (paclitaxel)
Placebo, docetaxel	Placebo, docetaxel	Akeso	phase 3	Taxane; microtubule stabilizer	Beta-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthelmintic class)

· 2 drugs in this class
Swiss Tropical & Public Health Institute · 2 drugs in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). similar placebo to mebendazole — Competitive Intelligence Brief. https://druglandscape.com/ci/similar-placebo-to-mebendazole. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab